Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Status:
Completed
Trial end date:
2017-04-28
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the overall response rate (ORR), which
includes complete response (CR) and partial response (PR), to bendamustine treatment in
patients with indolent non-Hodgkin lymphoma (NHL) that has progressed after rituximab or a
rituximab-containing therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.